GB0212046D0 - Vaccines - Google Patents

Vaccines

Info

Publication number
GB0212046D0
GB0212046D0 GBGB0212046.7A GB0212046A GB0212046D0 GB 0212046 D0 GB0212046 D0 GB 0212046D0 GB 0212046 A GB0212046 A GB 0212046A GB 0212046 D0 GB0212046 D0 GB 0212046D0
Authority
GB
United Kingdom
Prior art keywords
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0212046.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0212046.7A priority Critical patent/GB0212046D0/en
Publication of GB0212046D0 publication Critical patent/GB0212046D0/en
Priority to TW092113870A priority patent/TW200407426A/zh
Priority to ARP030101782A priority patent/AR039846A1/es
Priority to NZ536668A priority patent/NZ536668A/en
Priority to KR10-2004-7018958A priority patent/KR20050004211A/ko
Priority to AU2003240729A priority patent/AU2003240729B2/en
Priority to EP03730134A priority patent/EP1527177A2/en
Priority to CNB038171988A priority patent/CN100408682C/zh
Priority to JP2004508299A priority patent/JP2005526520A/ja
Priority to PCT/EP2003/005594 priority patent/WO2003100060A2/en
Priority to MXPA04011527A priority patent/MXPA04011527A/es
Priority to CA002485816A priority patent/CA2485816A1/en
Priority to RU2004134331/13A priority patent/RU2303069C2/ru
Priority to PL03374569A priority patent/PL374569A1/xx
Priority to US10/515,871 priority patent/US20060251665A1/en
Priority to BR0311211-0A priority patent/BR0311211A/pt
Priority to IL16515604A priority patent/IL165156A0/xx
Priority to IS7526A priority patent/IS7526A/is
Priority to NO20044947A priority patent/NO20044947L/no
Priority to ZA200409445A priority patent/ZA200409445B/xx
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0212046.7A 2002-05-24 2002-05-24 Vaccines Ceased GB0212046D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB0212046.7A GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines
TW092113870A TW200407426A (en) 2002-05-24 2003-05-22 Vaccines
ARP030101782A AR039846A1 (es) 2002-05-24 2003-05-22 Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo
BR0311211-0A BR0311211A (pt) 2002-05-24 2003-05-23 Molécula de ácido nucleico codificando um antìgeno de muc-1, plasmìdeo, proteìna, composição farmacêutica, usos de uma molécula de ácido nucleico e de uma proteìna, e, método para tratar ou prevenir tumores ou metástases
JP2004508299A JP2005526520A (ja) 2002-05-24 2003-05-23 Ｖｎｔｒ反復ユニットの数が減少したｍｕｃ−１抗原
RU2004134331/13A RU2303069C2 (ru) 2002-05-24 2003-05-23 Антиген muc1 со сниженным числом повторяющихся vntr-блоков
AU2003240729A AU2003240729B2 (en) 2002-05-24 2003-05-23 MUC-1 antigen with reduced number of VNTR repeat units
EP03730134A EP1527177A2 (en) 2002-05-24 2003-05-23 Muc-1 antigen with reduced number of vntr repeat units
CNB038171988A CN100408682C (zh) 2002-05-24 2003-05-23 具有数目减少的vntr重复单位的muc-1抗原
NZ536668A NZ536668A (en) 2002-05-24 2003-05-23 An epithelial cell mucin MUC-1 antigen, which is capable of raising an immune response in vivo and is stable and has reduced susceptibility to recombination with respect to full-length MUC-1 (also known as episialin or polymorphic epithelial mucin, PEM)
PCT/EP2003/005594 WO2003100060A2 (en) 2002-05-24 2003-05-23 Muc-1 antigen with reduced number of vntr repeat units
MXPA04011527A MXPA04011527A (es) 2002-05-24 2003-05-23 Antigeno de muc-1 con numero de unidades de repeticion de vntr reducidas.
CA002485816A CA2485816A1 (en) 2002-05-24 2003-05-23 Vaccines
KR10-2004-7018958A KR20050004211A (ko) 2002-05-24 2003-05-23 Ｖｎｔｒ 반복 유닛의 수가 감소된 ｍｕｃ-1 항원
PL03374569A PL374569A1 (en) 2002-05-24 2003-05-23 Vaccines
US10/515,871 US20060251665A1 (en) 2002-05-24 2003-05-23 Vaccines
IL16515604A IL165156A0 (en) 2002-05-24 2004-11-10 A nucleic acid molecule encoding an antigen capable of raising on immune response
IS7526A IS7526A (is) 2002-05-24 2004-11-11 MUC-1 mótefnavaki með skertan fjölda af VNTR endurtekninga einingum
NO20044947A NO20044947L (no) 2002-05-24 2004-11-12 MUC-1 antigen med redusert antall VNTR gjentagene enheter
ZA200409445A ZA200409445B (en) 2002-05-24 2004-11-23 MUC-1 antigen with reduced numbr of VNTR repeat units.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0212046.7A GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines

Publications (1)

Publication Number Publication Date
GB0212046D0 true GB0212046D0 (en) 2002-07-03

Family

ID=9937394

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0212046.7A Ceased GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines

Country Status (20)

Country Link
US (1) US20060251665A1 (enExample)
EP (1) EP1527177A2 (enExample)
JP (1) JP2005526520A (enExample)
KR (1) KR20050004211A (enExample)
CN (1) CN100408682C (enExample)
AR (1) AR039846A1 (enExample)
AU (1) AU2003240729B2 (enExample)
BR (1) BR0311211A (enExample)
CA (1) CA2485816A1 (enExample)
GB (1) GB0212046D0 (enExample)
IL (1) IL165156A0 (enExample)
IS (1) IS7526A (enExample)
MX (1) MXPA04011527A (enExample)
NO (1) NO20044947L (enExample)
NZ (1) NZ536668A (enExample)
PL (1) PL374569A1 (enExample)
RU (1) RU2303069C2 (enExample)
TW (1) TW200407426A (enExample)
WO (1) WO2003100060A2 (enExample)
ZA (1) ZA200409445B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
ES2476990T3 (es) * 2003-11-12 2014-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sistema para tratar y prevenir cáncer de mama
JP5285855B2 (ja) * 2003-11-12 2013-09-11 アメリカ合衆国 膵癌を処置および予防するためのカスタムベクター
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
WO2011156751A2 (en) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
CN106215179A (zh) * 2010-06-11 2016-12-14 乔治亚大学研究基金公司 免疫原性疫苗
KR20140023903A (ko) * 2011-02-24 2014-02-27 온코타이레온, 인코포레이티드 항원보강제를 갖는 muc1 기초 당지질펩티드 백신
SG11201805621SA (en) * 2016-01-19 2018-08-30 Pfizer Cancer vaccines
US11052139B2 (en) 2016-09-28 2021-07-06 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK70598A3 (en) * 1995-11-30 1999-04-13 Univ Texas Methods and compositions for the diagnosis and treatment of cancer
AU727308B2 (en) * 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
WO2002062319A2 (en) * 2001-01-19 2002-08-15 Corixa Corporation Microsphere delivery of mucin peptides
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US20060069238A1 (en) * 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
IS7526A (is) 2004-11-11
CN1668746A (zh) 2005-09-14
NO20044947D0 (no) 2004-11-12
MXPA04011527A (es) 2005-09-30
RU2303069C2 (ru) 2007-07-20
JP2005526520A (ja) 2005-09-08
KR20050004211A (ko) 2005-01-12
PL374569A1 (en) 2005-10-31
RU2004134331A (ru) 2005-08-27
US20060251665A1 (en) 2006-11-09
NO20044947L (no) 2005-12-16
EP1527177A2 (en) 2005-05-04
TW200407426A (en) 2004-05-16
NZ536668A (en) 2007-01-26
CA2485816A1 (en) 2003-12-04
IL165156A0 (en) 2005-12-18
WO2003100060A3 (en) 2004-02-19
AU2003240729A1 (en) 2003-12-12
AR039846A1 (es) 2005-03-02
AU2003240729B2 (en) 2007-12-20
ZA200409445B (en) 2006-02-22
WO2003100060A2 (en) 2003-12-04
BR0311211A (pt) 2005-03-01
CN100408682C (zh) 2008-08-06

Similar Documents

Publication Publication Date Title
GB0213622D0 (en) Vaccine Corporation
GB0226722D0 (en) Vaccine
GB0202901D0 (en) Novel vaccine
GB0225788D0 (en) Vaccine
GB0225786D0 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0228715D0 (en) Vaccine
GB0323840D0 (en) Vaccines
GB0209878D0 (en) Vaccine
GB0218921D0 (en) Novel vaccine
PL376534A1 (pl) Szczepionka
GB0321614D0 (en) Vaccines
AU2003237701A8 (en) Vaccines
GB0304634D0 (en) Vaccines
GB0206595D0 (en) Vaccine
IL156434A0 (en) Vaccine
GB0223355D0 (en) Vaccine
GB0226179D0 (en) Vaccine
GB0330007D0 (en) Vaccines
GB0217721D0 (en) Vaccines
GB0206462D0 (en) Vaccines
GB0200829D0 (en) Vaccines
GB0206575D0 (en) Vaccine
GB0219626D0 (en) Vaccine
GB0220211D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)